Hisun Braces For Hit From US FDA Import Alert
This article was originally published in PharmAsia News
Zhejiang Hisun Pharmaceutical has already seen its net profit slump this year, and now has to face a US import alert for APIs made at one of its Chinese plants on top of a voluntarily quarantine by importers in Canada. The company is nevertheless pushing ahead with the reconstruction of its business model, eyeing global partners for future markets.
Register for our free email digests: